Evotec SE (NASDAQ:EVO) Expected to Earn FY2024 Earnings of ($0.10) Per Share

Evotec SE (NASDAQ:EVO) – Investment analysts at HC Wainwright issued their FY2024 EPS estimates for shares of Evotec in a research note issued on Thursday, April 25th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings per share of ($0.10) for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Evotec’s FY2025 earnings at $0.02 EPS, FY2026 earnings at $0.36 EPS and FY2027 earnings at $0.42 EPS.

Other research analysts have also issued reports about the stock. Royal Bank of Canada raised shares of Evotec from a “sector perform” rating to an “outperform” rating in a report on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a “hold” rating to a “buy” rating in a report on Friday, April 12th.

Evotec Price Performance

Shares of EVO stock opened at $5.02 on Monday. Evotec has a 1-year low of $4.87 and a 1-year high of $13.49. The firm has a fifty day moving average of $7.24 and a two-hundred day moving average of $8.61.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of EVO. Mubadala Investment Co PJSC acquired a new position in shares of Evotec in the 4th quarter valued at about $53,931,000. Optiver Holding B.V. lifted its position in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares during the last quarter. Finally, Quadrant Capital Group LLC bought a new stake in Evotec in the 4th quarter valued at about $25,000. 5.81% of the stock is owned by institutional investors and hedge funds.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.